Satellite Bio

📍 Cambridge, United States🗓 Founded 2019👥 43 employees💰 Last funded 2021
Biotechnology Research🌐 satellite.bio
Website LinkedIn
At Satellite Bio, we’re on a journey – a quest to treat some of the most elusive diseases known to humankind by pioneering Tissue Therapeutics, an entirely new category of regenerative medicine. With the first-of-its-kind SAT (Satellite Adaptive Tissues) platform, Satellite Bio can turn virtually any cell type into bioengineered tissues that are integrated into the body to restore natural function. These tissues, called Satellites, can deliver the comprehensive cellular response needed to repair or even replace critical organ functions in patients with diseases caused by the interaction of genetic and environmental factors. The SAT platform is an unprecedented technology with the potential to drive a pipeline of sophisticated cell-based therapeutic solutions that tackle a broad range of elusive diseases. Satellite Bio’s quest is as audacious as it is clear: bring new hope to patients and families suffering from elusive diseases. Tissue Therapeutics is how it will deliver on that promise—and why it is deeply committed to leading and realizing the potential of this exciting new frontier in regenerative medicine.
2
Total investors
2
Early stage
0
Mid stage
0
Late stage
2019
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Satellite Bio?
Satellite Bio has 2 investors on record on gritt.io, including 2 early-stage backers.
When did Satellite Bio last raise funding?
The most recent investment in Satellite Bio recorded on gritt.io was in 2021.
When was Satellite Bio founded?
Satellite Bio was founded in 2019.
What industry is Satellite Bio in?
Satellite Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Satellite Bio based?
Satellite Bio is headquartered in Cambridge, United States.